t e c h n i c a l r e p o r t s Many proteins have been proposed to act as surrogate markers of organ damage, yet for many candidates the essential biomarker characteristics that link the protein to the injured organ have not yet been described. We generated an Ngal reporter mouse by inserting a double-fusion reporter gene encoding luciferase-2 and mCherry (Luc2-mC) into the Ngal (Lcn2) locus. The Ngal-Luc2-mC reporter accurately recapitulated the endogenous message and illuminated injuries in vivo in real time. In the kidney, Ngal-Luc2-mC imaging showed a sensitive, rapid, dose-dependent, reversible, and organ-and cell-specific relationship with tubular stress, which correlated with the level of urinary Ngal (uNgal). Unexpectedly, specific cells of the distal nephron were the source of uNgal. Cells isolated from Ngal-Luc2-mC mice also revealed both the onset and the resolution of the injury, and the actions of NF-kB inhibitors and antibiotics during infection. Thus, imaging of Ngal-Luc2-mC mice and cells identified injurious and reparative agents that affect kidney damage.
Organ damage induces the appearance of many different proteins in serum and in urine, and some of these have been proposed as surrogate measures of tissue damage. However, such a 'biomarker' must meet a number of criteria: (i) the protein must originate from injured cells, rather than from uninjured 'bystanders'; (ii) the amount of the protein in the biofluid must be proportional to its expression in the injured organ, and this quantity should reflect a graded, dose-dependent response to damage; (iii) the appearance of the biomarker should be temporally related to the inciting stimulus, so as to alert the clinician to a potentially reversible stage of the illness; (iv) the expression of the biomarker should rapidly decay when the acute phase of injury has terminated; (v) the expression of the protein should be conserved across many patient populations and various animal models; and (vi) the biomarker should be a crucial component of organ pathophysiology.
Although studies have demonstrated the statistical power of different biomarkers, research has yet to fulfill even the most basic requirement that serum or urine concentrations of a candidate biomarker are proportional to their expression at the site of injury in vivo. These data could be obtained by longitudinal measurements in the damaged organ itself and in the biofluid, but methodology has been limited to intermittent sampling, which cannot convincingly associate organ injury with biofluid measurements. In addition, candidate biomarkers that are expressed in multiple organs must be investigated with tissue-specific knockouts to link the biomarker to the damaged organ. Hence, a new technology is needed for repetitive real-time analysis of the injured organ and the biofluid.
The current diagnosis of acute kidney injury (AKI) relies not on measurement of a marker of acute injury but instead on a marker of steady-state kidney function, muscle-derived serum creatinine (sCr). In non-steady-state conditions, such as AKI, however, sCr is a retrospective, insensitive and even deceptive measure of kidney injury. sCr is retrospective because it must accumulate over many days, a length of time that is regulated by extra-renal modifiers such as muscle mass and diet 1 . The marker is insensitive because as much as a 50% loss of renal function may be required to elevate sCr enough that it comes to medical attention, whereas levels that fall short of this threshold are usually dismissed, despite their known association with excess mortality and prolonged hospitalization 2 . sCr is deceptive because its level often reflects transient physiologic adaptations to volume changes or the presence of chronic kidney disease, rather than AKI. Most importantly, the measurement of sCr does not identify the cell type that is acutely injured, even though this localization determines the natural history of the disease and its response to therapy 3 . These drawbacks call for new methods that can identify injured cells in the initial phases of AKI.
Neutrophil gelatinase-associated lipocalin (Ngal) was first reported in ischemic kidneys using gene arrays 4 and then in hospitalized patients using immunoblots 5 . Subsequent studies in adults 6 , children 7 , mice 5, 8 , rats and pigs have shown that serum and urine Ngal (sNgal and uNgal, respectively) are upregulated in the biofluid after ischemiareperfusion injury, hypoxia, drug toxicity and bacterial infections 5,8,9 , The Ngal reporter mouse detects the response of the kidney to injury in real time before sCr is elevated. However, like most candidate biomarkers, the source of the protein, its relationship to damage in vivo and the mechanisms of its expression are poorly defined, necessitating the use of animal models to resolve these fundamental issues.
To find out whether Ngal protein fulfills the criteria of a biomarker, we developed a reporter mouse to compare the time course of Ngal gene and protein expression in vivo. Using this model, we investigated the sensitivity, kinetics, dose-dependency, reversibility and organ and cellular specificity of Ngal expression. Real-time imaging identified the pathways that activate Ngal and the site of injury where kidney Ngal produces uNgal.
RESULTS

Generation of the Ngal double-fusion reporter mouse
We generated the Ngal double-fusion reporter mouse by knocking a double-fusion reporter gene encoding Luc2-mC into a site between the 5′ untranslated region (UTR) and the start codon of the Ngal gene, so that the double-fusion reporter is driven by the endogenous Ngal promoter and its 5′ UTR ( Supplementary Fig. 1 Fig. 2 ) before bacterial artificial chromosome (BAC) recombineering ( Supplementary Fig. 1a ). Ngal-targeted kv1 embryonic stem cells ( Supplementary Fig. 1c and Supplementary Fig. 3 ) upregulated expression of Ngal-Luc2-mC in response to treatment with sodium cyanide (1 mM) or lipid A (4 µg ml −1 ), demonstrating that the knockin was functional. The F 1 heterozygous Ngal-Luc2-mC mice were identified by PCR genotyping (Supplementary Fig. 1b,d) , by long-distance PCR ( Supplementary  Fig. 1b,e ) and by DNA sequencing of the integration sites.
Ngal-Luc2-mC mouse reports kidney injury
Unilateral ischemia (ischemia-reperfusion, 15 or 30 min) in either the right or the left kidney of either male or female mice induced Ngal-Luc2-mC activity specifically in the operated kidney (n = 8; Fig. 1a and Supplementary Fig. 4 ). In contrast, the contralateral kidney and the extra-renal organs did not express high levels of Ngal-Luc2-mC. The specificity of the reporter was confirmed in sectioned kidneys, which emitted luminescence from the medulla of the injured kidney ( Fig. 1b ; 12 h after 30 min ischemia) but not from the contralateral, uninjured kidney (Fig. 1b) .
The time course of Luc2-mC expression was visualized in living mice. We found markedly increased bioluminescence and fluorescence (about a tenfold increase) 3-6 h after renal artery clamping (Fig. 1a,c and Supplementary Fig. 4a ) and peak expression (~25-to 80-fold increase) 12 h after ischemia ( Fig. 1c and Supplementary  Fig. 4a ). The intensity of the response depended on the ischemic dose: for example, Ngal-Luc2 activity rose 25-or 70-fold after a 15-min or a 30-min dose of ischemia, respectively ( Fig. 1c) . Kidney Ngal-Luc2 and uNgal were strictly correlated, both temporally and in the intensity of their responses, implying that the protein originated from the kidney ( Fig. 1d and Supplementary Fig. 4b ).
Because sCr was unchanged in unilateral kidney injury, we compared Ngal-Luc2-mC and sCr in bilateral ischemia-reperfusion Supplementary Fig. 5a ). In this model, Ngal-Luc2 rose between 3 and 6 h after ischemia ( Fig. 1f ; significance compared to time 0 was as follows: 3 h, P = 0.085; 6 h, P = 0.0009; 12 h, P = 0.008; 24 h, P = 0.04; 48 h, P = 0.12), as did uNgal expression ( Fig. 1g ) but sCr lagged by 12 h (Fig. 1f ; compared to time 0: 3 h, P = 0.35; 6 h, P = 0.18; 12 h, P = 0.028; 24 h, P = 0.055; 48 h, P = 0.15). Significant changes in urine creatinine (uCr) were detectable only when urine was collected at 3-h intervals (Fig. 1f) ; uCr fell within a narrow interval of time (compared to time 0: 0-3 h, 0.22-fold change, P = 0.027; 3-6 h, 0.41-fold change, P = 0.15), then returned to steady state (6-12 h, 1.08-fold change, P = 0.31; 12-24 h, 1.27-fold change, P = 0.19; 24-48 h, 1.22-fold change, P = 0.15). The data show that Ngal-Luc2-mC and uNgal were more sensitive, rapid and dynamic measures of AKI than were sCr and uCr 10 , confirming our earlier results in mice 8 and humans 6, 11 . Likewise, other biomarkers such as N-acetyl-beta-dglucosaminidase were delayed (data not shown).
Next we examined whether Ngal-Luc2-mC expression reported nephrotoxic damage. Kidney Ngal-Luc2-mC and uNgal ( Fig. 2a,b) were markedly upregulated after mice were exposed to cisplatin (20 mg kg −1 ). Cells extracted from Ngal-Luc2-mC kidneys also responded to cisplatin (10 µM; Fig. 2c) , implying a direct effect. Lipid A, the purified lipid component of endotoxin, induced dosedependent increases in Ngal-Luc2-mC expression (intraperitoneal doses of 5, 15 and 30 mg per kg body weight lipid A induced 17.3-, 21.5-and 33.9-fold increases in Ngal-Luc2, respectively; n = 6) in many organs including kidney, liver, lung, spleen and trachea ( Fig. 2d) . Kidney Ngal-Luc2 was most pronounced at 30 mg kg −1 lipid A, mirroring the dose-dependent increase in sCr ( Fig. 2e) . Lung Ngal-Luc2 was most pronounced when lipid A was aspirated ( Supplementary Fig. 5b) , producing a typical luminescent pattern 12 . Hence, although we found little expression of Ngal-Luc2-mC outside of the kidney in response to cisplatin and nonuremic ischemia-reperfusion 13 , Ngal-Luc2-mC also revealed the effect of toxins that injure multiple organs.
The kidney is the source of urinary Ngal Previously, uNgal has been used as a quantitative surrogate for kidney Ngal, but no experimental evidence has validated this linkage. Although kidney Ngal-Luc2-mC and uNgal were expressed simultaneously in our experiments, these data were insufficient to show that the kidney is the major source of uNgal.
To examine whether uNgal originated in the kidney, we performed kidney cross-transplants between Ngal knockout (Ngal −/− ) and wildtype C57BL/6 mice (Ngal +/+ ), followed by renal artery clamping (10 min). There was a 228.1 ± 18.8-fold and a 184.6 ± 56.7-fold induction of Ngal mRNA (measured by quantitative PCR) in ischemic wild-type kidneys (respectively, in Ngal +/+ kidneys transplanted into Ngal +/+ hosts, n = 6; and in Ngal +/+ kidneys into Ngal −/− hosts, n = 4), whereas there was only a 6.3 ± 0.86-fold Ngal induction in the ischemic knockout kidney (Ngal −/− kidneys into Ngal +/+ hosts, n = 5) ( Supplementary Fig. 6a ). Consistent with this, uNgal protein levels rose in Ngal +/+ kidneys transplanted to Ngal +/+ or Ngal −/− hosts, whereas smaller increases in uNgal were found in Ngal −/− kidneys transplanted to Ngal +/+ hosts (P < 0.005 at 12 h and P < 0.02 at 24 h; Supplementary Fig. 6b ). Infiltrating RNA + cells or small amounts of sNgal might explain the small amount of uNgal apparently present in Ngal −/− kidney recipients; the former explanation is more tenable because Ngal message was detected in Ngal −/− kidneys, and after ischemia-reperfusion, less 25 I-sNgal (0.21 ± 0.04-fold less; 1 µg, intraperitoneal) reached the urine than in unoperated mice. In all of the cross-transplants, Havcr1 (Kim1), a biomarker of AKI, was upregulated after ischemia (about ninefold), confirming kidney injury. In contrast, liver Ngal was not activated, demonstrating the specificity of the surgical manipulation. Likewise, deletion of neutrophils 14 by RB-6 antibodies (Supplementary Fig. 7 ) did not alter expression of kidney Ngal. Together, the specific expression of kidney Ngal-Luc2-mC in surgical models and the strict correlation between kidney and urinary Ngal kinetics indicate that uNgal originates predominately from kidney epithelia.
The damaged nephron is the source of Ngal in the kidney To determine the cellular source of Ngal, we dissected reporter kidneys 24 h after ischemia-reperfusion (15-min dose). Ngal RNA and mC fluorescence were detected in the thick ascending limbs of Henle (TAL), the macula densa, and the intercalated cells of the collecting ducts after treatment by ischemia or lipid A (Figs. 2f,g and 3 and Supplementary Figs. 8-10) .
The distal convoluted tubule also expressed Ngal but at a lower level, and no expression was seen in proximal tubules ( Fig. 3a-d) . By costaining the hybridization with v-ATPase B1/2 antibodies, we found that α-type intercalated cells (apical v-ATPase) expressed Ngal (Fig. 3e-g) . A very similar pattern of Ngal expression was also found in the kidney after treatment with lipid A (15 mg kg −1 ), except that inner medullary tubules were accentuated ( Fig. 2f,g) , perhaps owing to the local concentration of lipid A or Toll-like receptors 15, 16 . Obstruction of the ureter also induced Ngal expression in inner medullary tubules (Supplementary Fig. 8d ).
Next, we examined whether Ngal originated from injured nephrons or from adjacent uninjured bystanders. We did this by comparing the site of Ngal expression with post-ischemic (30-min ischemia; Jablonski score of 3) or post-lipid A tubular morphology. Ngal was found in tubules in the outer strip of the outer medulla, which generally showed dilation and attenuation or intraluminal debris or casts ( Figs. 2 and 3) . When we clamped a polar (segmental) artery for 30 min, cast-filled inner medullary tubules expressed Ngal, whereas tubules in the nonischemic domain did not express Ngal (Fig. 3h,i) . In summary, Ngal expression appeared specifically in distal tubular segments of injured nephrons, and it was not expressed in nonischemic zones.
Ngal-Luc2-mC is not induced by volume depletion
Volume depletion (pre-renal azotemia) is a physiological adaptation that is characterized by few anatomical changes but that confuses the diagnosis of AKI by elevating sCr. We found that mild pre-renal azotemia produced hypernatremia (average serum sodium rose 8 ± 2.5 mmol l −1 ; n = 3), reduced body weight (21.7% ± 4%) and caused a small rise in sCr (0.3 ± 0.2 mg dl −1 ) but did not increase Ngal-Luc2-mC expression in any organ (n = 3; Fig. 4 ). Hence Ngal-Luc2-mC distinguished AKI from volume depletion, consistent with human studies 6 .
Expression of Ngal reflects pharmacological interventions
Uropathogenic Escherichia coli are the principal cause of urogenital infection. As Ngal is a bacteriostatic protein mediating innate immune responses by sequestering iron from bacteria 17 , we tested whether Ngal responded to E. coli CFT073 (ref. 18 ). Ngal-Luc2 was upregulated by CFT073 in primary Ngal-Luc2-mC kidney cells ( Fig. 5a; 2.9 ± 0.4-fold increase, P = 0.042), correlating with bacterial counts (data not shown). Brief treatment with gentamicin (100 µg ml −1 ) suppressed the Ngal reporter (no antibiotic compared with antibiotic, P = 0.034), particularly when gentamicin was used as a pretreatment rather than after bacterial growth. Uropathogenic bacteria activate NF-κB signaling by binding to Toll-like receptors such as TLR4 (ref. 8) . Because previous studies have suggested that Ngal may be a target of NF-κB 19 , we determined whether Ngal is suppressed when NF-κB is blocked. Lipid A (4 µg ml −1 ) activated Ngal-Luc2 (197 ± 3.2%) in primary kidney cells compared to DMSO control (Fig. 5b) , but when these cells were pretreated (1 h) with MG132 (a selective proteasome inhibitor 20 ; 0.5-5 µM) or novel NF-κB inhibitors 21, 22 (Supplementary  Fig. 11; 5 µM) , Ngal-Luc2 activity was inhibited 15-90% in a dosedependent manner. For example, novel compound A reduced Ngal-Luc2 expression to 13.5 ± 0.1 of lipid A treatment (Fig. 5b) . These results indicate that NF-κB is important in Ngal regulation.
Because primary kidney cultures contain cells from many parts of the nephron, we examined whether lipid A-responsive Ngal-Luc2 expression originated from cortical or medullary tubular cells. Cortical and medullary regions of the reporter kidneys were dissected; to check that cells were separated correctly, we measured expression of the mRNAs aquaporin-1, aquaporin-2 and uromodulin (Aqp1, Aqp2 and Umod, markers for proximal tubules, distal tubules and collecting , respectively) by quantitative PCR (Fig. 5c) . As expected, primary cells isolated from the inner medulla and papilla of Ngal-Luc2-mC kidneys showed enrichment of distal tubular markers Aqp2 and Umod, and de-enrichment of Aqp1, a proximal tubular marker. When these two pools of cells were treated with lipid A (4 µg ml −1 ), medullary cells showed intensive Ngal-Luc2 expression compared with the cortical population (4.48 × 10 4 ± 5.24 × 10 3 photons per mg total protein in medullary cells; 1.26 × 10 4 ± 2.49 × 10 3 photons per mg total protein in cortical cells; Fig. 5d ). These data confirm that medullary cells upregulate Ngal-Luc2 in response to bacteria and lipid A.
DISCUSSION
We selected the Ngal promoter to detect cellular stress and injury because a large body of literature shows that Ngal is intensely expressed after injury of humans and animals 5, 6, 8, 9, 23 . Ngal protein appears early in the course of disease, anticipating the diagnosis of AKI 8 and even patient death 6, [24] [25] [26] . In the injury, Ngal is essential in defense against bacterial invasion, acting by restricting iron traffic 27 . Each of these characteristics suggested that we might be able to use the endogenous promoter and its 5′ UTR to visualize injury by placing Luc2-mC under their control.
Using the reporter mouse, we tested the relationship between kidney Ngal and uNgal in real time. Ngal-Luc2-mC could be quantified in individual organs, and Luc2-mC, lacking signal sequences, accumulated in injured cells. We found that (i) the timing and the intensity of kidney Ngal-Luc2-mC and uNgal were correlated; (ii) both kidney Ngal-Luc2-mC and uNgal were dependent on the dose of injury; (iii) the kidney was the principal or the only site of Luc2-mC expression in careful unilateral or bilateral surgeries, indicating that uNgal production derived from the kidney; (iv) TAL and collecting duct cells activated Ngal-Luc2-mC in vitro and in vivo in response to the same stressors, implying that uNgal is produced in a cell-autonomous manner; (v) the expression of Ngal-Luc2-mC in segmental ischemia implied that uNgal was an autonomous feature of the damaged nephron or the result of localized signaling among damaged nephrons; (vi) uNgal was independent of sNgal, as Ngal −/− hosts implanted with Ngal +/+ kidneys generated uNgal; and (vii) kidney Ngal expression was unaffected by neutrophil deletion. We conclude that kidney Ngal generated uNgal. In contrast, a small amount of sNgal may reach the urine 5 from the liver 17 , neutrophils 14 or perhaps from the kidney itself (as demonstrated in cross-transplants; data not shown), escaping degradation in proximal tubules 5 (see model in Supplementary Fig. 12) .
Results from the reporter mice also showed that the activation of the Ngal gene was more sensitive and rapid than the accumulation of sCr and was independent of the complexities of uCr measurements 10 . For example, unilateral or segmental kidney ischemia or low doses of lipid A were detected by Ngal-Luc2-mC reporters even while the majority of the kidney was unaffected and sCr unchanged. Additionally, Ngal-Luc2-mC could detect kidney injury as early as 3-6 h after its onset and by 12 h could distinguish different doses of ischemia, whereas sCr was statistically elevated only 12 h after bilateral ischemic kidney damage. Thus, tests for Ngal expression might be able to detect the earliest stage of renal injury caused by medications 23 or by diseases that may otherwise be clinically silent (for example, early sepsis, unilateral obstructive uropathy), and Ngal-Luc2-mC may also be useful for monitoring therapies that mitigate kidney injury 28 . For example, Ngal-Luc2-mC is suppressed when the pathway is interrupted upstream by antibiotics and downstream by NF-kB inhibitors.
The TAL and collecting ducts were unexpected sources of uNgal, but then again these segments are known to respond to various forms of AKI (reviewed in ref. 29) . Dilation and flattening of the epithelia, activation of apoptotic pathways 4 and the shedding of cells (especially α-intercalated cells) 30, 31 have been observed in these segments. However, compared with the proximal tubule, damage appears to be mitigated by growth factors 32 , HIF 29, 33 , and ERK and the redistribution of corticomedullary circulation 34 . In fact, Ngal-expressing cells in the TAL and collecting ducts did not appear apoptotic (Supplementary Fig. 9 ). Hence, during their response to a number of insults, the survival of the TAL and collecting ducts may permit them to 'report' nephron injury by expressing Ngal, whereas necrosis of proximal segments may render this compartment a more variable source for measuring a de novo genetic response.
Here we report a technique for evaluating inherent features of a candidate biomarker to report cell stress and injury in vivo, in real time, at the site of injury. The Ngal-Luc2-mC mouse showed the quantitative linkage between cell stress, kidney Ngal and uNgal. We propose that this type of analysis may generally be required to demonstrate the usefulness of a biomarker. For example, although cardiac troponin and kidney Ngal may both quantify the degree of injury (the prospective infarct size 35 or RIFLE score 8, 36 ) and predict clinical outcomes (cardiac death 37 or renal replacement therapy 6, 24, 26, 36 ), the two markers are dissimilar in that troponin is a preformed protein released from injured cells, whereas Ngal and other biomarkers require de novo expression and hence must be monitored at the transcriptional level. These rigorous methods should also be applied to more complex models (for example, pre-existing chronic kidney disease 38, 39 ) in which the ratio between organ and biofluid expression may be different than in an acute injury. We conclude that the Ngal-Luc2-mC mouse represents a noninvasive method of continuous and quantitative detection of gene expression in vivo, permitting longitudinal assessment of organs undergoing stress in real time.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
